Skip to main content
AmigoFish

Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism

From Eagle's Eye View: Your Weekly CV Update From ACC.org · · 7 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial (https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063) in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults.

Subscribe to Eagle's Eye View

Back to Eagle's Eye View: Your Weekly CV Update From ACC.org · Report a problem